Pharmacokinetic and Safety Comparison of Two Capecitabine Tablets in Patients With Colorectal or Breast Cancer
NCT04420871
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
48
Enrollment
OTHER
Sponsor class
Conditions
Patient Participation
Interventions
DRUG:
150 mg of Xeloda®
DRUG:
150 mg of capecitabine
Sponsor
The Affiliated Hospital of Qingdao University